| Literature DB >> 34069345 |
Gerald Mboowa1,2, Dickson Aruhomukama2,3, Ivan Sserwadda2, Freddy Eric Kitutu4, Hayk Davtyan5, Philip Owiti6, Edward Mberu Kamau7, Wendemagegn Enbiale8,9, Anthony Reid10, Douglas Bulafu11, Jeffrey Kisukye3, Margaret Lubwama3, Henry Kajumbula3.
Abstract
Antimicrobial Resistance (AMR) and Healthcare Associated Infections (HAIs) are major global public health challenges in our time. This study provides a broader and updated overview of AMR trends in surgical wards of Mulago National Referral Hospital (MNRH) between 2014 and 2018. Laboratory data on the antimicrobial susceptibility profiles of bacterial isolates from 428 patient samples were available. The most common samples were as follows: tracheal aspirates (36.5%), pus swabs (28.0%), and blood (20.6%). Klebsiella (21.7%), Acinetobacter (17.5%), and Staphylococcus species (12.4%) were the most common isolates. The resistance patterns for different antimicrobials were: penicillins (40-100%), cephalosporins (30-100%), β-lactamase inhibitor combinations (70-100%), carbapenems (10-100%), polymyxin E (0-7%), aminoglycosides (50-100%), sulphonamides (80-100%), fluoroquinolones (40-70%), macrolides (40-100%), lincosamides (10-45%), phenicols (40-70%), nitrofurans (0-25%), and glycopeptide (0-20%). This study demonstrated a sustained increase in resistance among the most commonly used antibiotics in Uganda over the five-year study period. It implies ongoing hospital-based monitoring and surveillance of AMR patterns are needed to inform antibiotic prescribing, and to contribute to national and global AMR profiles. It also suggests continued emphasis on infection prevention and control practices (IPC), including antibiotic stewardship. Ultimately, laboratory capacity for timely bacteriological culture and sensitivity testing will provide a rational choice of antibiotics for HAI.Entities:
Keywords: Mulago National Referral Hospital (MNRH); Structured Operational Research and Training IniTiative (SORT IT); Uganda; antimicrobial resistance (AMR); surgical wards; trends
Year: 2021 PMID: 34069345 PMCID: PMC8163195 DOI: 10.3390/tropicalmed6020082
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
The antibiotic classes and their respective abbreviations.
| Antibiotic Classes | Antibiotics (Abbreviation) |
|---|---|
| Penicillins | penicillin (PEN), ampicillin (AMP), piperacillin (PIPERAC), piperacillin-tazobactam (TPZ), oxacillin (OXACILL), amoxicillin-clavulanic acid (AMOXCLAV) |
| Third generation cephalosporins | cefotaxime (CEFOTAX), ceftriaxone (CEFTRIA), ceftazidime (CAZ) |
| Macrolides | erythromycin (ERYTH) |
| Second generation cephalosporins | cefuroxime (CXM) |
| Sulphonamides | trimethoprim-sulfamethoxazole (SXT) |
| Aminoglycoside | gentamicin (GENTA), amikacin (AMIKACI), high-level aminoglycoside (HLAR), |
| Tetracycline | tetracycline (TETRAC) |
| Phenicols | chloramphenicol (CHLORAM) |
| Fluoroquinolones | ciprofloxacin (CIPROFL) |
| Carbapenems | meropenem (MEROP), imipenem (IMIPENE) |
| Lincosamides | clindamycin (CLINDA) |
| Oxazolidinones | linezolid (LINEZOL) |
| Polymyxin E | colistin (CT) |
| Nitrofurans | nitrofurantoin (NITROFU) |
| Glycopeptide | vancomycin (VANCO) |
| Fourth-generation cephalosporin | cefepime (CEFEPIM) |
Culture samples collected from patients attending the surgical wards of Mulago National Referral Hospital, Uganda, from 2014 to 2018.
| Sample | Frequency (n = 428) | Percentage (%) |
|---|---|---|
| Tracheal aspirate | 156 | (36.5) |
| Pus swab | 120 | (28.0) |
| Blood | 88 | (20.6) |
| Urine | 22 | (5.1) |
| Pus aspirate | 20 | (4.7) |
| Catheter tip | 13 | (3.0) |
| High vaginal swab | 3 | (0.7) |
| Ear swab | 3 | (0.7) |
| Wound swab | 2 | (0.5) |
| Stool | 1 | (0.2) |
Bacteria isolated from samples taken from patients attending the surgical wards of Mulago National Referral Hospital, Uganda, from 2014 to 2018.
| Classification | Frequency (n = 428) | Percentage (%) | |
|---|---|---|---|
| Gram-negative | 93 | (21.7) | |
|
| 68 | (15.9) | |
| 19 | (4.4) | ||
| 18 | (4.2) | ||
| 11 | (2.6) | ||
|
| 4 | (0.9) | |
| 3 | (0.7) | ||
| Gram-negative | 75 | (17.5) | |
| 47 | (11.0) | ||
| Gram-positive | 53 | (12.4) | |
| 26 | (6.1) | ||
| 9 | (2.1) | ||
| Corynebacteria | 2 | (0.5) | |
Figure 1Antimicrobial susceptibility profiles of bacterial isolates from surgical wards of Mulago National Referral Hospital, Uganda, from 2014, 2016, and 2018.
Figure 2(A) Antimicrobial resistance trends among Gram-positive bacterial isolates for 2014, 2016, and 2018; (B) Antimicrobial resistance trends among Gram-negative bacterial isolates of samples collected from the surgical wards of MNRH, Uganda, for 2014, 2016, and 2018.
Resistance of Gram-positive isolates towards antibiotics from 2014 to 2018.
| Antibiotic/Years | 2014 | 2015 | 2016 | 2017 | 2018 | Chi2 Value for Trends | |
|---|---|---|---|---|---|---|---|
|
| 18 (94.7) | 16 (88.9) | 10 (100.0) | 7 (77.8) | 7 (77.8) | 2.13 | 0.144 |
|
| 10 (47.6) | 13 (68.4) | 21 (100.0) | 8 (72.7) | 9 (100.0) | 9.94 | 0.002 |
|
| 11 (84.6) | 6 (40.0) | 3 (60.0) | 2 (40.0) | 4 (100.0) | 0.03 | 0.871 |
|
| 4 (30.8) | 2 (18.2) | 0 (0.0) | 1 (14.3) | 3 (42.9) | 0.01 | 0.938 |
|
| 0 (0.0) | 1 (50.0) | 3 (100) | 0 (0.0) | 2 (40.0) | 0.08 | 0.778 |
|
| 2 (100.0) | 2 (100.0) | - | 2 (50.0) | 0 (0.0) | 3.56 | 0.059 |
There was a statistically significant increased trend in resistance towards erythromycin from 47.6% in 2014 to 100% in 2018 (x2 trends = 9.94, p-value < 0.001). The bold shows statistically significant value.
Resistance of Gram-negative isolates towards antibiotics from 2014 to 2018.
| Antibiotic/Year | 2014 n (%) | 2015 n (%) | 2016 n (%) | 2017 n (%) | 2018 n (%) | Chi2 Value for Trends | |
|---|---|---|---|---|---|---|---|
| Ampicillin | 76 (95.0) | 34 (100.0) | 41 (97.6) | 44 (97.8) | 30 (96.8) | 0.27 | 0.603 |
| Gentamicin | 70 (63.1) | 19 (61.3) | 30 (51.7) | 42 (57.5) | 55 (76.4) | 0.72 | 0.397 |
| Piperacillin | 3 (37.5) | 7 (58.3) | 6 (66.7) | 16 (64.0) | 39 (83.0) | 9.58 | 0.002 |
| Cefotaxime | 58 (74.4) | 9 (42.9) | 32 (76.2) | 30 (75.0) | 39 (78.0) | 1.72 | 0.189 |
| Piperacillin-Tazobactam | 8 (30.8) | 7 (21.9) | 11 (36.7) | 19 (41.3) | 30 (49.2) | 14.83 | <0.001 |
| Cefotaxime | 22 (71.0) | 3 (33.3) | 27 (79.4) | 27 (93.1) | 7 (100) | 8.02 | 0.005 |
| Ceftriaxone | 58 (84.1) | 11 (61.1) | 21 (80.8) | 34 (89.5) | 53 (98.2) | 9.95 | 0.008 |
| Trimethoprim-sulfamethoxazole | 74 (90.2) | 35 (87.5) | 23 (92.0) | 39 (90.7) | 49 (96.1) | 1.34 | 0.245 |
| Amikacin | 6 (15.6) | 6 (15.6) | 4 (14.3) | 9 (20.9) | 18 (37.5) | 7.01 | 0.008 |
| Amoxicillin clavulanic acid | 52 (92.9) | 31 (93.9) | 16 (76.2) | 24 (80.0) | 25 (86.2) | 0.84 | 0.361 |
| Cefepime | 9 (64.3) | 4 (40.0) | 7 (63.6) | 24 (63.2) | 33 (75.0) | 2.25 | 0.134 |
| Ciprofloxacin | 38 (57.6) | 18 (42.9) | 17 (47.2) | 38 (58.5) | 37 (61.7) | 2.01 | 0.156 |
| Imipenem | 4 (5.7) | 1 (3.3) | 3 (8.1) | 14 (22.6) | 25 (37.9) | 32.29 | <0.001 |
| Meropenem | 3 (25.0) | 2 (100.0) | 1 (33.3) | 1 (14.3) | 4 (50.0) | 0.36 | 0.547 |
| Tetracycline | 10 (62.5) | 8 (47.1) | 15 (62.5) | 8 (44.4) | 14 (73.7) | 0.56 | 0.453 |
| Chloramphenicol | 31 (66.0) | 22 (50.0) | 19 (45.2) | 28 (59.6) | 17 (63.0) | 0.03 | 0.863 |
| Nitrofurantoin | 0 (0.0) | 0 (0.0) | - | 2 (22.2) | 0 (0.0) | 0.84 | 0.358 |
| Cefuroxime | 54 (91.5) | 15 (53.6) | 16 (76.2) | 33 (89.2) | 30 (96.8) | 1.87 | 0.171 |
| Colistin | - | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (6.25) | 0.49 | 0.483 |
Note: * p-value < 0.05. There was a statistically significant increased trend in resistance of the isolates towards piperacillin (x2 trends = 9.58, p-value = 0.02); TPZ (x2 trends = 14.83, p-value < 0.001); cefotaxime (x2 trends = 8.02, p-value = 0.005); ceftriaxone (x2 trends = 9.95, p-value = 0.008); amikacin (x2 trends = 7.01, p-value = 0.008); and imipenem (x2 trends = 36.4, p-value < 0.001) from the year 2014 to 2018. The bold shows statistically significant value.